10-KPeriod: FY2005

ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2005

Filed March 16, 2006For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2005 annual report, highlighting its pioneering work in RNA interference (RNAi) therapeutics. The company is focused on developing novel drugs that leverage the natural RNAi mechanism to selectively silence gene activity, addressing a broad range of diseases. ALNY's most advanced candidate, ALN-RSV01 for RSV infection, has entered Phase I clinical trials, with a pandemic flu therapeutic candidate expected to reach the IND stage by the end of 2006. The company's strategy centers on building a robust pipeline of proprietary RNAi therapeutics and forming strategic alliances with major pharmaceutical companies like Novartis and Merck. These collaborations are crucial for Alnylam's financial and operational growth, providing significant funding and development expertise. Alnylam has also secured a strong intellectual property portfolio, which it considers vital for its competitive advantage. Despite early-stage development and significant investment in research and development, Alnylam remains focused on its long-term vision of establishing RNAi therapeutics as a major drug class.

Key Highlights

  • 1Alnylam Pharmaceuticals is focused on developing RNA interference (RNAi) therapeutics, a potentially new class of drugs.
  • 2The company's most advanced product candidate, ALN-RSV01 for Respiratory Syncytial Virus (RSV) infection, has entered Phase I clinical trials.
  • 3Alnylam has a strategic alliance with Novartis for RNAi therapeutics, including a collaboration for a pandemic flu therapeutic expected to reach IND submission by the end of 2006.
  • 4Other key collaborations are in place with Merck for RNAi technology and therapeutics in various disease areas, and with Medtronic for drug-device combinations for neurodegenerative diseases.
  • 5The company emphasizes building a strong intellectual property portfolio covering fundamental aspects of RNAi and its therapeutic applications.
  • 6Alnylam has incurred significant research and development expenses, reflecting its commitment to advancing its pipeline, and expects to require substantial additional funding.
  • 7The company has no commercial manufacturing capabilities and relies on third-party manufacturers.

Frequently Asked Questions

Alnylam Pharmaceuticals is focused on developing and commercializing RNA interference (RNAi) therapeutics. RNAi is a natural cellular mechanism that silences specific genes, and Alnylam aims to leverage this for a new class of drugs to treat a wide range of diseases.

As of the filing date, Alnylam's most advanced product candidate is ALN-RSV01, which is in Phase I clinical trials for RSV infection. The company also expects to submit an Investigational New Drug (IND) application for a pandemic flu RNAi therapeutic by the end of 2006. Alnylam has multiple discovery programs in areas like cystic fibrosis, spinal cord injury, Parkinson's disease, and ocular diseases.

Alnylam's funding primarily comes from strategic alliances and collaborations with major pharmaceutical companies like Novartis and Merck, which provide upfront payments, research funding, milestone payments, and royalties. The company also raised capital through equity offerings.

Key risks highlighted include the unproven nature of RNAi technology for therapeutics, the company's early-stage status with a history of losses and no product revenues, the need for substantial future funding, dependence on third-party collaborators and manufacturers, potential intellectual property challenges, and the competitive landscape in the biopharmaceutical industry.